Marcos de Lima, MD, came to Ohio State from Case Western Reserve University to serve as a professor in the Division of Hematology and as director of both the Blood and Marrow Transplant (BMT) and Cellular Therapy programs at the OSUCCC – James. His appointments were effective April 1. Previously, de Lima was co-leader of the Hematopoietic and Immune Cancer Biology Program at Case Comprehensive Cancer Center, director of the Bone Marrow Transplant Program at University Hospitals Cleveland Medical Center, and director of the Hematologic Malignancies and Stem Cell Transplant Program at University Hospitals Seidman Cancer Center. He has years of experience in developing and conducting clinical trials involving stem cell transplantation for cancers originating in blood-borne tissue, bone marrow or immune system cells.
Christa Nagel, MD, has joined Ohio State’s College of Medicine as an associate professor in the Division of Gynecologic Oncology. Nagel was recruited from Case Western Reserve University School of Medicine, where she had been an assistant professor in the Division of Reproductive Biology since 2014. She was also an attending physician in the Division of Gynecologic Oncology at University Hospitals Cleveland Medical Center and on the Gynecologic Cancer Care Team at University Hospitals Seidman Cancer Center. She’s a national leader in minimally invasive surgery, including laparoscopic and robotic surgery. Nagel has served on National Comprehensive Cancer Network guidelines committees for endometrial cancer, gestational trophoblastic disease, and cervical, vaginal and vulvar cancers. She earned her MD and served her residency at Ohio State before doing fellowship training at The University of Texas Southwestern Medical Center.
Mark Rubinstein, PhD, was recruited from the Medical University of South Carolina (MUSC) and the Hollings Cancer Center to serve as an associate professor in the Division of Medical Oncology at Ohio State and as a researcher in the Pelotonia Institute for Immuno-Oncology at the OSUCCC – James, where he’s also in the Translational Therapeutics Program. Rubinstein’s NIH-funded research program focuses on understanding how the immune system functions and on applying this knowledge to the development of immune-based therapies to treat cancer. As part of this effort, his laboratory is working to develop improved adoptive cell therapy and immune checkpoint therapy strategies. Rubinstein earned his bachelor’s degree at the University of Virginia and his PhD at MUSC. He completed his postdoctoral studies at the University of California, San Diego, and the Scripps Research Institute in La Jolla, Calif.